Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in NNOX.
← Back to Free Index

NNOX

Analysis as of: 2026-10-21
Nano-X Imaging Ltd.
Nanox sells digital tomosynthesis imaging systems plus AI, cloud, teleradiology, marketplace and health IT services for medical imaging workflows.
ai cloud healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Distress-priced option on community imaging utility
The equity is priced more like a financing problem than a commercial platform. If runway is secured and active sites begin producing routine reimbursed scans, a credible niche imaging utility can emerge; if not, dilution remains the main compounding engine.

Analysis

Thesis
Nanox is a distressed but real option on turning a cleared low-footprint imaging device plus workflow, teleradiology and health IT into a recurring community-imaging utility; if it secures runway and proves scan utilization at activated sites, 2031 revenue can compound far faster than the market now prices, though the business should still be valued like mixed medtech-services rather than pure software.
Last Economy Alignment
Cheaper AI and coordination help Nanox bundle imaging, workflow and remote reads for underserved sites, but weak defaultness and financing fragility keep the score only moderately positive.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
23.8x (from 5 most recent analyses)
Reasoning
The upside case does not require Nanox to become a dominant imaging OEM. It only requires survival, then proof that activated sites can produce recurring scans and pull through workflow, reading and health IT revenue. If that happens, investors can stop valuing it as a going-concern problem and start valuing it as a small imaging utility. Even then, I keep the multiple conservative because reimbursement, field operations and hardware still shape margins.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is a sequence-risk equity. Nanox first needs financing stability and listing continuity, then proof that activated sites can generate routine reimbursed scan volume, and only then can its broader workflow stack earn a durable multiple. The upside is real because the starting valuation is distressed; the danger is that dilution and slow site economics absorb the benefit before the flywheel forms.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.26
They are trying to control the scanner, the workflow and the remote reader in one loop, which AI can make cheaper and faster. But they do not yet own the default network, and if funding or trust breaks before utilization scales, bigger incumbents can squeeze them out.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$4.13
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case